Naprod Life Sciences has secured the renewal of its ANVISA Good Manufacturing Practice (GMP) certification for its manufacturing facility located in Tarapur, Maharashtra, reinforcing its regulatory compliance status and supporting its contract manufacturing operations in regulated export markets.

The renewal was granted following a successful inspection by Brazil’s health regulator ANVISA, which confirmed that the Tarapur facility continues to meet the stringent quality and manufacturing standards required for pharmaceutical production. ANVISA certification is a mandatory requirement for companies supplying pharmaceutical products to the Brazilian market and is widely recognised as a key benchmark for regulatory compliance in Latin America and other regulated regions.

The Tarapur plant is engaged in the manufacturing of injectable and oncology formulations, which require high levels of quality control, process validation and compliance oversight. The renewal of the GMP certification ensures continuity of supply to existing international clients, while also enabling the company to pursue additional export opportunities in markets that accept or rely on ANVISA approvals as part of their regulatory framework.

For Naprod Life Sciences, the renewal is significant from a business perspective as it allows the company to maintain uninterrupted access to the Brazilian pharmaceutical market, one of the largest and most regulated markets in the region. Regulatory clearances such as ANVISA GMP are essential for participating in long-term supply contracts, tender-based procurement programmes and contract manufacturing agreements with global pharmaceutical companies.

The certification also strengthens the company’s credibility as a contract manufacturing organisation (CMO) serving regulated markets. Compliance with ANVISA standards signals robust quality systems, validated manufacturing processes and consistent adherence to international GMP norms, all of which are critical factors for multinational pharma partners when selecting manufacturing vendors.

The Tarapur facility plays a key role in Naprod’s export-oriented manufacturing strategy, particularly in sterile and complex dosage forms, where regulatory approvals act as a gateway to sustained commercial engagement. The renewal supports Naprod’s ability to continue building its export pipeline, expand customer relationships and explore new regulated market opportunities without regulatory disruption.

The ANVISA GMP renewal aligns with the company’s ongoing focus on maintaining multiple international regulatory approvals to support business growth across global markets. By retaining compliance with key regulatory authorities, Naprod Life Sciences continues to strengthen its position in the contract manufacturing space while supporting long-term export-driven revenue streams.

As regulatory scrutiny continues to increase across global pharma markets, maintaining approvals such as ANVISA GMP remains a critical enabler for contract manufacturers seeking consistent growth and deeper integration into the global pharmaceutical supply chain.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!